Regeneron Pharmaceuticals Inc (REGN) : Sectoral Asset Management Inc reduced its stake in Regeneron Pharmaceuticals Inc by 1.49% during the most recent quarter end. The investment management company now holds a total of 232,770 shares of Regeneron Pharmaceuticals Inc which is valued at $86 Million after selling 3,530 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Regeneron Pharmaceuticals Inc makes up approximately 4.17% of Sectoral Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Susquehanna International Group Llp reduced its stake in REGN by selling 3,281 shares or 8.14% in the most recent quarter. The Hedge Fund company now holds 37,023 shares of REGN which is valued at $13.7 Million. Regeneron Pharmaceuticals Inc makes up approx 0.04% of Susquehanna International Group Llp’s portfolio.March Altus Capital Management Lp reduced its stake in REGN by selling 625 shares or 21.43% in the most recent quarter. The Hedge Fund company now holds 2,291 shares of REGN which is valued at $846,433. Regeneron Pharmaceuticals Inc makes up approx 8.52% of March Altus Capital Management Lp’s portfolio.Blackrock Advisors reduced its stake in REGN by selling 71,521 shares or 27.25% in the most recent quarter. The Hedge Fund company now holds 190,945 shares of REGN which is valued at $70.5 Million. Regeneron Pharmaceuticals Inc makes up approx 0.08% of Blackrock Advisors’s portfolio.California Public Employees Retirement System boosted its stake in REGN in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 209,100 shares of Regeneron Pharmaceuticals Inc which is valued at $77.4 Million. Regeneron Pharmaceuticals Inc makes up approx 0.12% of California Public Employees Retirement System’s portfolio.
Regeneron Pharmaceuticals Inc closed down -3.21 points or -0.81% at $394.49 with 9,60,065 shares getting traded on Wednesday. Post opening the session at $399.95, the shares hit an intraday low of $392.91 and an intraday high of $400.99 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.55. The company had revenue of $1201.00 million for the quarter, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.